DULUTH, Ga.--(BUSINESS WIRE)--Sep 3, 2025--
Launching now in the U.S., INGELVAC CIRCOFLEX ® AD is the first vaccine to combine both PCV2a and PCV2d antigens in a single dose designed for optimized herd health. Built on the industry-leading vaccine INGELVAC CIRCOFLEX ® from Boehringer Ingelheim, which has set the global standard for PCV2 protection for nearly 20 years, this new dual-antigen approach offers producers an additional option to protect their pigs and support long-term profitability.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250903677503/en/
Product shot of INGELVAC CIRCOFLEX® AD - a new PCV2 vaccine from Boehringer Ingelheim
PCV2 is one of the most prevalent and economically significant viruses in swine production. Porcine circovirus associated disease (PCVAD) is caused by the PCV2 virus and can lead to severe weight loss, difficulty breathing, and diarrhea. It impairs the immune system, enhancing co-infections and leaving pigs more susceptible to other swine diseases affecting the respiratory, reproductive and digestive systems.
While several genotypes have been identified, the industry has observed a clear shift over the past decade, with PCV2d becoming the predominant genotype in the U.S. and globally. 1,2 The broad protection provided by INGELVAC CIRCOFLEX ® AD was designed with this shifting landscape in mind, advancing pig health and sustaining viable businesses for producers.
Supporting pig producers through efficacy and convenience
“Our customers can count on us for continuous vaccine innovation. With INGELVAC CIRCOFLEX ® AD, we’re further advancing protection against evolving PCV2 threats with both PCV2a and PCV2d antigens combined. These two genotypes are responsible for over 90% of clinical cases, 1 and we are the first company to offer both antigens in a single dose,” said Gerard Ensink, Global Head of Swine at Boehringer Ingelheim. “We’ll continue to closely monitor PCV2 and other diseases impacting pig performance to help producers stay ahead of emerging risks.”
A vaccine that provides broad cross-protection is essential for effective PCV2 control. To maximize herd productivity, it is also important to manage co-infections, implement robust biosecurity measures, and maintain a thorough understanding of disease epidemiology.
“We’re excited to bring INGELVAC CIRCOFLEX ® AD to the U.S. market first, delivering the latest innovation in PCV2 protection,” shared Steve Boren, Vice President, U.S. Livestock at Boehringer Ingelheim. “In an industry where disease is a constant challenge, this next-generation vaccine offers broader, safer, longer-lasting immunity against the most prevalent PCV2 genotypes and can help proactively strengthen a herd’s immune system to reduce the risk and impact of co-infections. INGELVAC CIRCOFLEX ® AD reflects Boehringer Ingelheim’s long-standing commitment to PCV2 control and empowering producers to manage herd health with greater confidence.”
INGELVAC CIRCOFLEX ® AD is approved for use in healthy pigs as early as two weeks of age. It is administered intramuscularly via a single, 1-mL dose, with onset of immunity two weeks post-vaccination and a duration of immunity of at least six months. The vaccine includes Boehringer’s trusted water-based IMPRANFLEX ® adjuvant. It helps contribute to a robust immune response and limits the risk of injection-site reactions for safe, efficacious delivery of next-generation PCV2 protection. INGELVAC CIRCOFLEX ® AD is available in 50-dose and 250-dose presentations. Click here for additional product information.
References: |
| 1 Iowa State Veterinary Diagnostic Laboratory. |
2 Franzo G, Tucciarone CM, Legnardi M, Drigo M, Segalés J. An updated phylogeography and population dynamics of porcine circovirus 2 genotypes: Are they reaching an equilibrium? Frontiers in Microbiology. 2024;15:1500498. doi: 10.3389/fmicb.2024.1500498. |
Boehringer Ingelheim - Animal Health business
Boehringer Ingelheim provides innovation for preventing and treating diseases in animals. The company offers a wide range of vaccines, parasite-control products, and medicines for pets, horses, and livestock to veterinarians, animal owners, farmers, and governments. As a leader in animal health, Boehringer Ingelheim values that the health of humans and animals is deeply connected and strives to make a difference for people, animals, and society. Learn more at www.boehringer-ingelheim.com/animal-health.
Boehringer Ingelheim
Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in Research and Development, the company focuses on developing innovative therapies in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. More than 53,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow. Learn more at www.boehringer-ingelheim.com.
INGELVAC CIRCOFLEX ® and IMPRANFLEX ® are registered trademarks of Boehringer Ingelheim Vetmedica GmbH, used under license. ©2025 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All rights reserved. US-SWN-0086-2025
View source version on businesswire.com:https://www.businesswire.com/news/home/20250903677503/en/
CONTACT: Elizabeth Breeding
Associate Director, Communications & PR
T (703) 946-0370
elizabeth.breeding@boehringer-ingelheim.com
KEYWORD: UNITED STATES NORTH AMERICA GEORGIA
INDUSTRY KEYWORD: PHARMACEUTICAL AGRICULTURE HEALTH NATURAL RESOURCES
SOURCE: Boehringer Ingelheim
Copyright Business Wire 2025.
PUB: 09/03/2025 09:00 AM/DISC: 09/03/2025 08:59 AM
http://www.businesswire.com/news/home/20250903677503/en
